Profit Pregame

How Walmart Aims to Boost Revenue While Saving Lives

The Fight Against High Insulin Prices Could Mean Big Profits

Prices of one of the most widely used medicines have reached unsustainable levels. This week’s big news is just what the doctor ordered for huge gains.

What’s happening?

For more than a decade now, the price of an incredibly important material has been on the rise. It’s something that millions of people around the globe rely on in their everyday lives, but which many are struggling to afford these days.

No, I’m not talking about steel, or lumber, or even semiconductors.

This product is far more important.

According to the World Health Organization, more than 463 million people are living with diabetes. And that number is projected to grow to as much as 700 million by 2045.

For those that suffer from diabetes, having affordable access to insulin is critical. And as prices for the life-saving drug have increased to as much as $2,300 per month or more for certain patients, many people are reaching a breaking point.

But Walmart Inc. (WMT) – one of the world’s largest retailers – is stepping up to offer relief from high insulin costs.

The announcement is being met with a lot fanfare this week, and it could have massive implications for investors, as well.

Where’s the money?

Walmart Inc. (WMT) announced yesterday that it will soon be offering its own brand of insulin.

Most significantly, the new ReliOn NovoLog insulin will retail for just $72.88 a vial – a 58% cost reduction from similar leading brands.

The offering is the result of a direct collaboration with the pharmaceutical company Novo Nordisk A/S (NVO), which will allow Walmart to streamline production and pass savings on to its customers.

The resulting revenue stream from the affordable insulin could be absolutely massive for Walmart. In the U.S. alone, roughly 34 million Americans have some type of diabetes.

Walmart’s new offering will provide and affordable and accessible choice for millions of them that have been struggling with the inflated cost of insulin.

And investors have already realized the enormous potential this move holds…

How do I get some?

Following the announcement, WMT traded as much as 3.8% higher yesterday.

I saw signals of huge call buyers hit S.C.A.N. all day, and some of those calls went up 100% in a matter of minutes or hours.

Ultimately, I think that Walmart will rip higher. But prospective buyers may want to exercise a little caution before jumping in.

Since it moved so much, in the short-term I am neutral on WMT stock. Those looking to make a quick buck on this news may want to look for a pullback before jumping in.

As a long-term trade, I am very bullish on WMT with this news, especially if this opens the door for more affordable medicines on Walmart’s shelves.

For those looking to make an options play to potentially maximize their profits, consider the WMT December 17, 2021 $155 Calls for no more than $2.50. S.C.A.N. has revealed that these options have been attracting a lot of buyers lately, and could see a big move in the coming days and weeks.

Catch the Next Big Opportunity Before the Rest of the Market

Using the incredible power of my S.C.A.N. system, I’m able to pinpoint exactly where the big institutional money is flowing.

I can see every move they make in real-time, and I track their moves to find the best opportunities to double your money in just a few short weeks or less.

Every Monday-Thursday, I show members of my 1450 Club research service the exact trades to make to play those movements for the biggest potential gains in our Live Trading Room.

They can see exactly what I’m tracking live, have the opportunity to ask questions in real-time, and receive trade recommendations with up-to-the-minute pricing.

So, if you want the trades, the fast action, and the education to boot – click here now to learn everything you need to know about the 1450 Club.

In the Spotlight: Another delay for Intel

As Intel Corporation (INTC) struggles to keep market share away from competitors like Advanced Micro Devices, Inc. (AMD) and NVIDIA Corporation (NVDA), its investors got more bad news this week.

Intel announced yet another delay to the launch of its next-generation chips in an effort to improve their performance.

Production has now been pushed back to early 2022 after the latest estimate pegged Intel to begin later this year.

This is now the second delay Intel investors have suffered through in as many years, while competitors move further ahead in the race to offer advanced microchips.

The delay comes at a terrible time, as the demand for server chips has spiked amid the shift towards cloud computing.

That shift will continue to generate massive opportunities for companies that are positioned to meet the growing demand. There will be a lot of eyes watching this industry, and I’ll be among them. Stay tuned for further developments and trade ideas.

Community Tips

Inline Feedbacks
View all comments